| Literature DB >> 28603978 |
Tyler K Allred1, Francesco Manoni1, Patrick G Harran1.
Abstract
This review examines the state of the art in synthesis as it relates to the building of complex architectures on scales sufficient to drive human drug trials. We focus on the relatively few instances in which a natural-product-based development candidate has been manufactured de novo, rather than semisynthetically. This summary provides a view of the strengths and weaknesses of current technologies, provides perspective on what one might consider a practical contribution, and hints at directions the field might take in the future.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28603978 DOI： 10.1021/acs.chemrev.7b00126
Source DB: PubMed Journal: Chem Rev ISSN： 0009-2665 Impact factor: 60.622